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Cervical cancer screeningHuman papillomavirus (HPV) gene expression is dramatically altered during cervical carcinogenesis. Because
dysregulated genes frequently show abnormal patterns of DNA methylation, we hypothesized that
comprehensive mapping of the HPV methylomes in cervical samples at different stages of progression
would reveal patterns of clinical signiﬁcance. To test this hypothesis, thirteen HPV16-positive samples were
obtained from women undergoing routine cervical cancer screening. Complete methylation data were
obtained for 98.7% of the HPV16 CpGs in all samples by bisulﬁte-sequencing. Most HPV16 CpGs were
unmethylated or methylated in only one sample. The other CpGs were methylated at levels ranging from 11%
to 100% of the HPV16 copies per sample. The results showed three major patterns and two variants of one
pattern. The patterns showed minimal or no methylation (A), low level methylation in the E1 and E6 genes
(B), and high level methylation at many CpGs in the E5/L2/L1 region (C). Generally, pattern A was associated
with negative cytology, pattern B with low-grade lesions, and pattern C with high-grade lesions. The severity
of the cervical lesions was then ranked by the HPV16 DNA methylation patterns and, independently, by the
pathologic diagnoses. Statistical analysis of the two rating methods showed highly signiﬁcant agreement. In
conclusion, analysis of the HPV16 DNA methylomes in clinical samples of cervical cells led to the
identiﬁcation of distinct methylation patterns which, after validation in larger studies, could have potential
utility as biomarkers of neoplastic cervical progression.© 2009 Elsevier Inc. All rights reserved.Introduction
Persistent high-risk human papillomavirus (HPV) infection is a
necessary cause of virtually all cases of cervical cancer. Routine
cytologic screening of Papanicolau-stained cervical cells has drama-
tically reduced the incidence of cervical cancer, but cytology is not an
ideal screening tool due to its low sensitivity for high-grade lesions
(Spitzer, 2002). This is why screening is typically repeated annually
and why more than 5% of cervical cytology results without an obvious
high-grade lesion (those with “atypical squamous cells of undeter-
mined signiﬁcance”) require close follow-up. The high cost of cervical
cancer prevention is due to the frequency of Pap testing, the large
number of cytologic and histologic follow-ups, and the expense of
treating high-grade CIN.
A new HPV prophylactic vaccine is expected to further reduce the
incidence of cervical cancer, although not for several years. Cervicalicine, Yale University School of
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ll rights reserved.cancer will continue to develop in unvaccinated women, the 3% of
American women already infected with cancer-associated HPVs
(Dunne et al., 2007) and women infected with high-risk types of
HPV not in the vaccine, which cause about 30% of cervical cancer. The
importance of continued cervical screening cannot be overempha-
sized, because inadequate screening in the post-vaccination era could
negatively impact on the control of cervical cancer (Goldhaber-Fiebert
et al., 2008)). At the same time however the sensitivity of cervical
cytology will decline (Goldhaber-Fiebert et al., 2008). This situation
urgently calls for the discovery of novel biomarkers of cervical
oncogenesis (Kiviat et al., 2008).
The hallmark of carcinogenesis is deregulation of cellular gene
expression. A major mechanism controlling gene expression is DNA
methylation. DNA methylation is a non-mutational, heritable and
reversible epigenetic process. It is critical for normal development and
cellular differentiation (Ballestar and Esteller, 2008), including
epithelial differentiation (Paradisi et al., 2008). While the basic
mechanism of DNA methylation has been known since the 1980s,
intensive efforts to understand its role in gene regulation are more
recent. Many studies indicate that the absence of DNAmethylation in a
Fig. 1. Distribution among cervical samples of methylated and unmethylated CpGs in
the HPV16 open reading frames and long control region. The diamonds represent CpGs
that were unmethylated in all samples (◊), methylated in a single sample (grey ), or
in multiple samples (♦). The number of CpGs in each ORF/LCR is listed to the right of
each schematic.
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correlated with gene silencing (Esteller, 2002). These studies are only
a start though, as the vast majority of CpGs occur outside promoters
and have not been surveyed systematically.
To better understand the role of DNA methylation in carcinoge-
nesis, there is great desire to compare normal vs. malignant cells for
differences in DNA methylation. Unfortunately the most accurate
method for mapping the methylation status of each CpG in a DNA
sequence, bisulﬁte-sequencing, is not cost-effective for this endeavor
due to the very large size of the human genome (Bernstein et al.,
2007). In contrast, bisulﬁte-sequencing is entirely sufﬁcient for
mapping the relatively tiny genomes of viruses. Viruses cause an
estimated 15% of all human cancers (zur Hausen, 1991), and their
study over the past thirty years has been integral to understanding
molecular processes that regulate both normal and transformed cells
(DiMaio and Miller, 2006).
Previous studies of HPV16 DNA methylation (Badal et al., 2003;
Kalantari et al., 2004) showed that the viral long control region (LCR)
and early region were relatively unmethylated in most cervical
lesions. In contrast the late gene L1, encoding the major viral capsid
protein, was methylated at several CpGs in cervical carcinoma cell
lines and most cervical carcinoma tissues, but not in most asympto-
matic infections. More variable results were reported for premalig-
nant lesions although low- and high-grade cervical intraepithelial
neoplasia were generally not analyzed individually (Badal et al., 2003;
Kalantari et al., 2004). Similar results have been reported for HPV18 in
cervical lesions (Badal et al., 2004; Kalantari et al., 2008a; Turan et al.,
2006, 2007) and for HPV16 in anal intraepithelial neoplasias (Wiley
et al., 2005), penile carcinomas (Kalantari et al., 2008b) and oral
squamous cell carcinomas (Balderas-Loaeza et al., 2007). These
studies established a trend for increasing HPV 16/18 DNA methyla-
tion, particularly in the L1 gene, with increasing lesion severity but
they did not identify individual CpGs whose methylation status
speciﬁcally correlated with the pathology. On the other hand, only a
small region the HPV 16 or HPV 18 genomewas previously mapped by
bisulﬁte-sequencing (Badal et al., 2004; Kalantari et al., 2008a; Turan
et al., 2006, 2007).
We hypothesized that comprehensive mapping of all 113 sites of
potential DNAmethylation in the HPV16 genomes contained in patient
samples of non-malignant cervical cells at different stages of progres-
sion might reveal patterns of diagnostic or prognostic signiﬁcance. We
report here the analysis of thirteen HPV16-positive non-malignant
samples from women undergoing routine cervical cancer screening.
HPV16 is the most common HPV type in anogenital cancer. The results
show three principal HPV16 DNAmethylation patterns, the heaviest of
which has two variants. Assuming that DNA methylation represses
HPV16 gene expression, the patterns are consonant with what is
known regarding the biology of HPV-associated malignant progres-
sion. Furthermore, they show signiﬁcant agreement with the cervical
diagnoses arrived at by pathologic examination.
Results
Identiﬁcation of HPV16-positive cervical samples
To identify samples of cervical cells containing HPV16 DNA, 72
samples collected for routine cervical screening were evaluated by
PCR using two primer pairs speciﬁc for different regions of the HPV16
genome. Thirteen samples that generated clear bands of the
appropriate sizes on agarose gels were selected for further study.
Bisulﬁte-conversion and primer design
The most accurate method for determining the methylation status
of every CpG in a DNA sequence is bisulﬁte-sequencing. In this
method, sodium bisulﬁte converts all unmethylated cytosines (C) touracils but leaves methylated Cs intact. PCR is then performed to
amplify the bisulﬁte-treated DNA and convert the uracils to thymines
(T). Finally the original status of each C in the PCR product is
determined by DNA sequencing, which shows C if the original C was
methylated (meCpG) or T if it was not (CpG). Preliminary studies
assessed the completeness of bisulﬁte-conversion using two sub-
strates. One was a plasmid containing the full-length genome of the
W12 isolate of HPV16 (Flores et al., 1999), which we methylated in
vitro and ampliﬁed with primers described below. The other was the
Universal Methylated DNA Standard, ampliﬁed with its own primers.
Both control assays demonstrated complete bisulﬁte-conversion.
As bisulﬁte-converted DNA contains only adenine, thymine and
guanosine, except at methylated cytosines, the HPV16 genome was
bisulﬁte-converted (in silico) for primer design. Twenty primer pairs
were designed to collectively amplify all 113 CpGs in the HPV16
genome (Supplementary Table 1). PCR ampliﬁcation conditions were
then optimized for each primer pair using the molecular clone of the
W12 isolate of HPV16 (Alazawi et al., 2002) after actual in vitro DNA
methylation and bisulﬁte-conversion.
PCR ampliﬁcation
The DNAs from the thirteen cervical samples were bisulﬁte-
converted and ampliﬁed with each of the ﬁrst twenty primer pairs
(Supplementary Table 1). This work required further optimization of
the PCR conditions for some products and some samples. Ultimately,
all PCR products were ampliﬁed from all samples, indicating that each
sample contained all parts of the HPV16 genome (data not shown).
The data suggest the presence of episomal HPV16 DNA but do not
exclude the possibility of integrated HPV16 DNA in the form of
concatamers or partially deleted/rearranged genomes, alone or in
combination with episomal copies. Integrated HPV16 DNA is found in
about 6% of CIN2 lesions and 19% of CIN3 lesions, while low-grade
lesions contain only episomal viral genomes (Vinokurova et al., 2008).
Complete and missing data
To determine which HPV 16 CpGs were methylated, the PCR
products from each cervical sample were sequenced in both
directions. In some cases, the DNA sequences were not fully readable.
In those cases and others, the relevant DNA samples were reampliﬁed
and again sequenced in both directions. The data showed that the HPV
16 sequences in all samples were essentially identical to the W12
variant (Flores et al., 1999) and that virtually all cytosines that were
not part of CpGs had been converted to thymines, i.e. methylated
CpAs, CpTs and CpGs were very rare.
Fig. 3.Heat map: relationship of the thirteen HPV16 DNAmethylation proﬁles. Shown is
the heat map derived by Cluster analysis and, above it, the corresponding dendrogram
with the sample numbers in black and P-values in red. The original values are shown
without scaling. Each branch is labeled with the corresponding HPV16 methylation
pattern (A, B or C). The CpGs are shown in the same order as they occur in the HPV16
genome; every fourth CpG is listed on the y-axis. Not shown are the 52 CpGs without
any methylation and the eight with partially missing data (see Supplementary Table 2).
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12 (Supplementary Table 2). The difﬁculty obtaining readable
sequence from product 12 was most likely due to secondary structure
resulting from an extraordinarily high concentration of A+T nucleo-
tides, the frequency of which would range from 86 to 88%, depending
the methylation frequency. In an attempt to obtain additional data,
two new primer pairs were designed that together ampliﬁed a region
containing the sequence of product 12 plus additional upstream and
downstream sequences (primers 12-1 and 12-2, Supplementary
Table 1). DNA sequencing of the new PCR products provided new
data for 12 CpGs with previously missing data.
A subset of samples still had partially missing data at eight CpGs
(Supplementary Table 2). Among the sampleswith complete data, ﬁve
of the eight CpGs were unmethylated and three were methylated at
low levels, ranging from 4.5 to 8.2% of the HPV16 copies. All together,
completemethylation datawere obtained for 1450 of the 1469 CpGs in
the thirteen samples (98.7%).Fig. 2. HPV16 DNA methylation proﬁles of the individual cervical samples. The HPV16
DNA methylation proﬁle of each sample at each potential methylation site is shown
(mean + standard error of the multiple sequencing reads). The numbers inside each plot
are the sample numbers and the adjacent letters are the HPV16 DNA methylation pattern
(A, B or C). Nucleotides other than the 113 CpGs are not shown. The organization of the
HPV16 genomewith sequential numberingof the CpGs is shownat thebottomof theﬁgure.
Fig. 4. HPV16 DNA methylation patterns (A–C) The panels show three HPV16 methylation patterns: (A–C) respectively. The x-axis is the same for all panels, but only the CpGs with
methylation in each pattern are labeled. The nucleotide numbers are those of the W12 isolate of HPV16 (Flores et al., 1999) (Genbank AF125673). The bars represent CpGs that were
methylated in only one sample per pattern (□); only two samples (patterns A and B) or two to four samples (pattern C) (grey ); and all ﬁve samples of pattern C (■). One sample in
pattern A was missing data at position 1509, and one in pattern C, at position 4247. Not shown are the 52 unmethylated CpGs. The y-axis shows the mean percentage of HPV16
genomes per sample with methylation at each CpG plus the S.E.M.
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The HPV16 genome contains 113 CpGs, and multiple CpGs occur in
each gene as well as the LCR. Direct sequencing of the individual PCR
products frequently showed the presence of C and T in different
reactions and/or C in one sequencing direction and T in the other. The
variation was probably due to the heterogeneity of the population of
HPV 16 molecules in the original sample, and hence PCR product, and
not to hemimethylation. This interpretation was also supported by
peaks that contained both C and T in some chromatograms (data not
shown).
To estimate the frequencies of methylation among the HPV16
copies per sample, we averaged the mean frequencies per sample,
calculated by averaging all the sequence data (2.7±0.1 readable
sequences per CpG per sample (mean±S.E.M.)). The frequency of
methylation at the individual meCpGs ranged from a mean of 11.1% (at
four CpGs with nine data points) to 100% of the HPV16 genomes per
sample. Fifty-two CpGs, including all in the E4 ORF, all but one in the
E7 ORF, and most in the E2 ORF were not methylated in any sample
(Fig.1). Thirty-two CpGsweremethylated in just one sample, and only
29 were methylated in multiple samples.
HPV16 DNA methylation patterns in clinical samples
We next examined the proﬁles of the HPV16 methylomes within
each sample. As shown in Fig. 2, most methylated CpGs wereheterogeneously methylated, as indicated by levels greater than 0
and less than 100% and by the error bars. From visual inspection
of the individual proﬁles three patterns were deduced (Fig. 2).
The ﬁrst six samples were completely or nearly completely
unmethylated (pattern A). The next two were methylated at
limited numbers of CpGs, primarily in the early region (pattern
B). The last ﬁve were heavily methylated at several CpGs, primarily
in the late region (pattern C). Overall, the number of CpGs
methylated per sample was 1.3±0.4 in pattern A, 9.0±1.0 in
pattern B, and 22.2±3. in pattern C (mean±S.E.M.). While
some meCpGs occurred in only one sample per pattern and
therefore were not part of the pattern per se, the different levels
indicate different degrees of susceptibility to DNA methylation (or
demethylation) at different stages of disease.
Cluster analysis: identiﬁcation of related subgroups of HPV16 DNA
methylation proﬁles
To further examine the relationships among the thirteen cervical
samples, the data were subjected to cluster analysis. As shown in
Fig. 3, the samples with patterns A and B formed one major branch
with two closely related subgroups, one consisting of the six samples
with pattern A, and the other, the two samples with pattern B. The
secondmajor branch contained the ﬁve samples with pattern C. As the
probabilities of the clusters occurring by chance were small (Fig. 3),
our visual impressions were validated.
Table 1
Methylated CpGs speciﬁc to pattern C and unique to the C-2 variant.
Feature location Cytosinea Methylation frequencyb
Speciﬁc to pattern C (variants C-1 and C-2)c
E5 3887 53.3±11.1
E5 3937 72.0±12.7
E5 3941 86.7±13.3
L2 4439 33.3±7.5
L2 5126 55.0±13.3
L2/L1 5600 60.3±4.8
L1 5707 81.7±9.3
L1 5724 76.7±12.2
L1 6387 56.7±11.7
Unique to variant C-2d
Enhancer 7533 100.0
Enhancer 7551 100.0
Enhancer 7674 100.0
Enhancere 7680 100.0
Enhancer 7692 100.0
Promoter 31 12.5
Promotere 38 12.5
Promoter 43 14.3
Promotere 52 20.0
E2 2988 50.0
L2 4424 50.0
L2 4537 80.0
L2 4904 33.3
L2 5171 0.0f
L1 6365 0.0g
L1 6794 50.0
L1 7032 33.3
a Position of the cytosine in the HPV16 genome.
b Percent of HPV16 genomes per sample with methylation (mean±S.E.M.).
c Each CpG was sequenced 3.9±0.3 times per sample (mean±S.E.M.).
d Each CpG was sequenced 4.7±0.4 times (mean±S.E.M.) in sample #19, with
variant pattern C-2.
e Cytosine located within an HPV16 E2 protein-binding site (E2BS).
f Methylated in all pattern C samples except #19 at 45.8%±19.7% of the HPV16 copies
per sample (mean±S.E.M.).
g Methylated in all pattern C samples except #19 at 74.2%±10.6% of the HPV16 copies
per sample (mean±S.E.M.).
Table 2
Lesion severity ranked by HPV16 DNA methylation pattern vs. pathologic diagnosis.
Pap
result
HPV16 DNA
methylation
pattern
Rank Pathologic diagnosis
Neg.a CIN1 CIN2/3
Rank
1 2 3
Neg.a A 1 #27b
Neg. A 1 #53
HSILc A 1 #343
ASC-USd B 2 #48
ASC-He B 2 #45
LSILf C-2 2 #19
ASC-US C-1 3 #353
ASC-US C-1 3 #18
ASC-US C-1 3 #49
ASC-US C-1 3 #321
a Cytologically negative for intraepithelial lesion or malignancy.
b Number of the cervical sample.
c High-grade squamous intraepithelial lesion.
d Atypical squamous cells of undetermined signiﬁcance.
e ASC-US cannot rule out HSIL.
f Low-grade squamous intraepithelial lesion (diagnosed as ASC-US before expert
review).
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features to the HPV16 genome. We also distinguished between CpGs
that were methylated in multiple samples (potentially part of a
pattern) vs. only one. In pattern A, up to three CpGs were methylated,
at low frequency, and they were located variously in the E1, L2 or L1
ORFs (Fig. 4A). Only one CpG in pattern A was methylated in two
samples (in the L2 gene) and none inmore than two. In pattern B, both
samples were methylated at four or ﬁve contiguous CpGs in the E6
open reading frame (ORF) (from position 125 to 387 in sample #45, or
position 494 to 539 in sample #48) (Fig. 4B). One (sample #45) also
wasmethylated in the LCR at the CpG in E2 binding site 4 (E2BS#4). In
pattern C, all ﬁve samples were heavily methylated at eleven CpGs
located in the E5/L2/L1 region, nine of which were pattern C-speciﬁc,
i.e. not methylated in any other sample. The nine pattern C-speciﬁc
CpGs included three of ﬁve in the E5 ORF, three of twenty in the L2
gene and four of nineteen in the L1 gene (one overlapping the L2
gene) (Fig. 4C) (for positions see Table 1). In summary, pattern A was
characterized by minimal methylation, pattern B by methylation in
the E1 and E6 ORFs, and pattern C by heavy methylation at nine
speciﬁc CpGs located at the end of the early region (E5) and in the L2
and L1 ORFs but not including the L1 terminus.
Correlation of pathology with HPV16 DNA methylation
The cervical cytology results and pathologic diagnoses were
reviewed by an expert cytopathologist (M.H.) and two expert
histopathologists (M.M. and G.K.H. III). Five samples were diagnosed
by cytology alone: two as negative, two as atypical squamous cells of
undetermined signiﬁcance (ASC-US, an equivocal diagnosis), and oneas a low-grade squamous intraepithelial lesion (LSIL). Four samples
with histologic follow-up were diagnosed as low-grade cervical
intraepithelial neoplasia (CIN1), and four others as high-grade CIN
(CIN2/3). We speculated that the high-grade lesions (CIN2/3) would
have pattern C because DNA methylation generally silences gene
expression and the heavily methylated HPV genes in pattern C are
silenced duringmalignant progression.We further speculated that the
negative samples would have pattern A, i.e. be the most different from
pattern C, and that the CIN1 lesions, being intermediate in severity,
would have an intermediate but functionally distinct level of
methylation, i.e. pattern B. Three samples with ASC-US or LSIL and
no follow-up had insufﬁcient data for deﬁnitive diagnosis. Of the other
samples, twowith pattern A had negative cytology, both samples with
pattern B showed signs of HPV infection and cervical intraepithelial
neoplasia grade 1 (CIN1), i.e. low-grade lesions, and three with
pattern C were high-grade lesions (CIN2/3) (Fig. 4). Thus seven of the
ten cases with deﬁnitive diagnoses had the predicted correlation.
One apparently discordant low-grade lesion with pattern C (#19)
was found upon re-review of the bisulﬁte-sequencing data to be
methylated at 15 CpGs that were not methylated in any other sample
(Table 1). It was also completely unmethylated at two CpGs that were
methylated in every other pattern C sample (Table 1). Re-review of the
cluster analysis reinforced the importance of the differentially
methylated CpGs because it showed that sample #19 was more
distantly related to the other pattern C samples than theywere to each
other, by a factor of approximately two (Fig. 3). Together, the data led
to the conclusion that sample #19 had a distinct variant of pattern C.
Pattern C was therefore divided into a C-2 variant represented by
sample #19 and a C-1 variant represented by the other samples.
The uniquely methylated CpGs in pattern C-2 (sample #19)
included nine in the LCR. Five of six in the keratinocyte-speciﬁc en-
hancer were completely methylated and four of the ﬁve in the E6/E7
promoter were lightly methylated (Table 1). Since DNAmethylation in
the 5′ regulatory regions of genes, including the HPV16 LCR (Kim et al.,
2003), usually represses expression of the gene(s) it controls, E6/E7
expression may have been compromised in sample #19.
The remaining two cases in which the HPV16 DNA methylation
pattern did not agree with the pathologic diagnoses showed no
meaningful differences in HPV16 methylation. One sample (#343)
clearly had HPV16 DNA methylation pattern A but showed a high-
grade lesion by both cytology and histology. The other one (sample
#353) had the high-risk variant of pattern C but was diagnosed as
CIN1. The early region of HPV16 in sample #353 was completely
devoid of methylation, while the same region of the other pattern C
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tiny difference was however insufﬁcient to consider the pattern of
sample #353 as a variant.
Finally, we evaluated the extent of agreement between the HPV16
DNA methylation patterns and the pathologic diagnoses, after
classifying pattern C-2 as a low-grade variant and excluding the
three samples without deﬁnitive diagnoses (Table 2). Statistical
analysis showed highly signiﬁcant concordance between the two
methods (P=0.005, Cohen's Kappa statistic).
Discussion
While it has been known for 25 years that papillomavirus genomes
are highly methylated in carcinomas (Wettstein and Stevens, 1983),
mapping the methylation status of speciﬁc sites began only recently.
Previous studies of HPV16 DNA methylation mapped up to 19 CpGs at
the 3′ end of the L1 ORF and the LCR (Badal et al., 2004; Kalantari et al.,
2004). We report here the precise mapping of 98.7% of all CpGs in the
HPV16 genomes contained in thirteen cellular samples of cervical cells
with pathologic diagnoses ranging from negative to CIN3. To our
knowledge, this is the ﬁrst report of comprehensive DNA methylation
mapping for the entire genome of any virus. It is also the ﬁrst to
identify unique HPV16 DNA methylation marks that distinguish high-
grade lesions from low-grade lesions and asymptomatic infections.
Most of the 113 CpGs in the HPV 16 genomewere unmethylated or
methylated in only one sample. The methylated CpGs were located
mainly in the bodies of HPV16 genes. CpG methylation within gene
bodies has been previously reported, but little is known about the
prevalence of such events nor their biologic signiﬁcance. Methylation
within a gene body might repress expression of the gene in which it
resides, another gene(s) via regulatory elements contained within the
ﬁrst gene, or merely reﬂect the stage of malignant progression in
neoplastic cells.
Repeat sequencing of the HPV 16 PCR products revealed hetero-
geneous methylation at most methylated CpGs, as previously reported
for smaller genomic regions by molecular cloning (Kalantari et al.,
2004; Turan et al., 2006, 2007). Despite the heterogeneity, the HPV16
methylomes in each sample showed one of three distinct patterns of
HPV16 DNA methylation or a variant of the most highly methylated
pattern. The existence of a limited number of patterns indicates that
transfer and/or removal of methyl groups to CpGs in the HPV16
genome is not a random process, that cells with methylation (or not)
at particular HPV16 CpGs have a selective growth advantage, and/or
that the methylation of certain CpGs is incompatible with continued
infection.
Pathologically, the samples with almost no HPV16 DNA methyla-
tion (pattern A) were the least severe, those with several methylated
CpGs in the E1 and E6 ORFs were intermediate in severity (pattern B),
and those with high frequency methylation, particularly in the E5/L2/
L1 region (pattern C), the most severe. Excluding three samples with
insufﬁcient pathology, the HPV16 DNA methylation patterns ranked
the severity of eight of ten lesions identically to the pathologic
diagnoses. Moreover the agreement was statistically signiﬁcant
(P=0.005). Thus neoplastic progression was generally associated
with increasing numbers of methylated CpGs and increasing propor-
tions of methylated HPV16 molecules, in agreement with previous
ﬁndings (Badal et al., 2003, 2004; Kalantari et al., 2004; Turan et al.,
2006, 2007). Our results also expand previous ﬁndings by identifying
nine speciﬁc CpGs in the E5 ORF, L2 ORF and 5′ two-thirds of the L1
gene that were highly methylated in high-grade lesions (Table 2).
High levels of HPV16 CpG methylation do not however necessarily
indicate a high-grade lesion, because the sample with by far the most
methylation was a low-grade lesion with the C-2 variant pattern. In
this lesion expression of the E6/E7 oncogenes may have been
repressed due to the methylation of more than 80% of the CpGs in
the enhancer/promoter region. Interestingly, the lesion sponta-neously regressed as shown by follow-up cytology one year after
biopsy. As the growth of transformed cervical cells relies on continued
E6/E7 expression (DeFilippis et al., 2003), it is tempting to speculate
that methylation of the HPV 16 enhancer/promoter region was
mechanistically involved in mediating regression. It is worth noting in
this context that complete methylation of the HPV 16 promoter/
enhancer region has previously been reported in a subset of asymp-
tomatic infections (Badal et al., 2003) that might have been
regressing.
The 3′ terminus of the L1 ORF was completely unmethylated in all
our samples. Previous bisulﬁte-sequencing studies have similarly
reported the absence of methylation at the L1 terminus in most
asymptomatic and low-grade cervical lesions as well as some high-
grade cervical lesions (Kalantari et al., 2004; Turan et al., 2006, 2007).
Other high-grade lesions however were highly methylated at the L1
terminus (Kalantari et al., 2004; Turan et al., 2006, 2007). Since DNA
methylation and HPV gene expression both change dramatically
during epithelial differentiation (Paradisi et al., 2008; Zheng and
Baker, 2006), and the L1 terminus of episomal HPV16 transits from a
hypermethylated state in undifferentiated cervical cells to a hypo-
methylated state upon the induction of differentiation (Kalantari et al.,
2008a), the absence of methylation at the L1 terminus in at least some
of our high-grade lesions may reﬂect the absence of undifferentiated
keratinocytes in cytology samples (this study) vs. tissues samples
(previous studies). The relative uniformity of epithelial differentiation
in our cervical samples may also have facilitated the identiﬁcation of
speciﬁc methylation differences between lesions with different
diagnoses.
There were two discordant cases. The low-grade lesion (CIN1)
with the C-1 methylation pattern was persistent as shown by follow-
up cytology (LSIL) seven months after the biopsy (sample #353). This
outcome suggests the possibility that the C-1 variant in a patient with
CIN1 could indicate persistence. Persistent lesions are at greatly
increased risk of malignant progression (Schiffman et al., 2005). The
other case was a high-grade lesion (HSIL and CIN2) with pattern A
(#343). In this case we suspect that the high-grade pathology was
caused by co-infection with a high-risk HPV type(s) other than HPV
16. Since concurrent HPV infections are common (Trottier et al.,
2006), the evaluation of HPV co-infection and the mapping of
additional HPV methylomes will be important in future studies.
In summary, HPV16 DNA methylation patterns have the potential
to provide useful biomarkers of cervical carcinogenesis. Future
validation studies will map the HPV methylomes in larger numbers
of cervical samples, infected (and co-infected) with various types of
HPV, and collected together with clinical follow-up data at multiple
time points. Such studies may identify speciﬁc combinations of HPV
methylation marks with deﬁnitive prognostic and/or diagnostic value
that could be easily be incorporated into routine screening assays.
Materials and methods
Origin of samples
Seventy-two residual samples of exfoliated cervical cells were
obtained from patients being routinely screened for cervical cancer by
the Department of Pathology at Yale University. The cervical cells were
collected in either PreservCyt® solution and held at room temperature
for approximately one month prior to use. The samples were collected
betweenMarch and October of 2007. The samples were obtained with
approval from the Yale Human Investigation Committee.
DNA puriﬁcation
Highmolecular weight DNAs were extracted from cervical samples
using MasterPure™ DNA puriﬁcation kits (EPICENTRE® Biotechnolo-
gies, Madison, WI 85201).
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Sample DNAs were screened for HPV16 DNA by PCR using two
primer pairs that ampliﬁed fragments containing nucleotides (nts) 79
to 559 or nts 1800 to 1942. PCR reactions were performed using Taq
PCR Master Mix Kits (Qiagen Inc., Valencia, CA 91355) with primers at
10 μm concentration. The PCR proﬁle was: 94 °C×5 min, followed by
35 cycles of 94 °C×20 s, 55 °C×45 s×72 °C for 1 min, with a ﬁnal
incubation at 72 °C for 10 min.
Bisulﬁte modiﬁcation
Sample DNAs were modiﬁed using the DNA Methylation-Gold
Kit™ (catalog number D5006, Zymo Research Corp., Orange, CA
92867) according to the manufacturer's instructions. To control for
complete bisulﬁte-conversion, we methylated a plasmid containing
the complete genome of the W12 isolate of HPV16 in vitro using the
CpG Methyltransferase SssI (New England Biolabs, Ipswich, MA) and
used it as a substrate. Other control reactions used the Universal
Methylated DNA Standard (catalog number D5010, (ZYMO Research,
Orange, CA 92867).
Ampliﬁcation of bisulﬁte-treated DNAs
Twenty-two pairs of primers were designed to amplify bisulﬁte-
modiﬁedHPV16DNAusing theMethPrimer Designprogram (urogene.
org/methprimer/index1.html) (Li and Dahiya, 2002). The primers are
listed in Table 1 without M13 tails, which were added to facilitate DNA
sequencing. The PCR ampliﬁcation conditions for each primer set were
optimized for MgCl2 concentration (1.5 to 4.0 μm) and annealing and
elongation temperature (50 °C to 68 °C). Each PCR reaction contained
1.25 units of AmpliTaq Gold (catalog number 808-0241) (Roche
Applied Science, Indianapolis, IN 46250) and 0.5 units of PfuTurbo®
polymerase (Stratagene, La Jolla, CA). The standard optimized PCR
proﬁlewas 95 °C×10min, followedbyﬁve cycles of 95 °C×1min, 54 °C
to 60 °C×2 min, 72 °C×3 min, and 35 cycles at 95 °C×1 min,
60 °C×2min, 72 °C×2min, with a ﬁnal incubation at 72 °C for 10min.
PCR reactionswereperformed in aMasterCycler®Gradient (Eppendorf
Scientiﬁc Inc., Westbury, NY 11590). The production of each PCR
product was conﬁrmed by electrophoresis in ethidium-bromide
stained agarose gels. Further optimization was required to amplify
some PCR products from several patient samples.
DNA sequencing
PCR products were puriﬁed and sequenced by Agencourt
Bioscience Corporation (Beverly, MA), and the DNA sequencing
data were analyzed using the multiple sequence alignment program
Clustal W (http://www.ebi.ac.uk/Tools/clustalw/).
Statistical analysis
Hierarchical clustering was performed using the hclust library
in the R statistical package (Team, 2007) using Ward's minimum
variance method with Euclidean distance metric. Above-average
expression is in red, whereas below-average expression is in green.
The dendrograms were generated as deﬁned for hierarchical cluster-
ing. Cluster stability was evaluated and permutation-based cluster
stability P-values calculated using the multi-scale permutation
clustering (R package ‘pvclust’ (Suzuki and Shimodaira, 2006)).
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